Core Scientific, Inc. Form 8-K Summary
Reporting date: November 16, 2023 event; filed and signed November 22, 2023. The filing concerns restructuring transactions during the company’s Chapter 11 bankruptcy cases, commenced December 21, 2022. The company continues operating as a debtor-in-possession. Its common stock and warrants trade on the OTC Pink Marketplace under CORZQ and CRZWQ.
Business Context and Restructuring
On November 16, 2023, Core Scientific and certain affiliates entered into a Restructuring Support Agreement with holders of approximately 93% of the April convertible notes, approximately 80% of the August convertible notes, the official equity committee, and participating equity committee members. The parties agreed to support the Third Amended Joint Chapter 11 Plan of Reorganization and related restructuring transactions.
Key Financial and Capital Structure Terms
| Item | Terms disclosed |
|---|---|
| April convertible notes secured claims | $350 million, plus applicable accrued interest and potential additional equity-related amounts. |
| August convertible notes secured claims | $360 million, plus applicable accrued interest and potential additional equity-related amounts. |
| Exit Facility | $40 million of new-money borrowing capacity, consisting of $20 million available at closing and $20 million available after closing, subject to conditions; plus a $40 million cashless facility reflecting converted convertible-note claims. |
| New secured notes | $150 million to holders of allowed April convertible-note secured claims. |
| New secured convertible notes | $260 million to holders of allowed convertible-note secured claims. |
| New common equity for convertible-note holders | $260 million of New Common Interests, based on Plan Value. |
| Equity Rights Offering | $55 million offering of shares in the reorganized company, priced using a 30% discount to Plan Equity Value and an assumed total enterprise value of $1.5 billion. |
| Backstop commitment | $37.1 million, severally and not jointly, by the Commitment Parties. |
| Backstop premium | 20% of the $37.1 million backstop commitment, payable in reorganized-company common stock if the offering and Plan are consummated. |
| Potential termination payment | 5% of the $37.1 million backstop commitment, generally payable upon specified termination events. |
The filing does not provide current-period revenue, net income, operating cash flow, cash balance, liquidity runway, operating margin, or debt-to-capital metrics.
Material Changes Versus the Prior Comparable Period
- The filing does not present a comparable-period income statement, balance sheet, or cash-flow analysis.
- The material development is the execution of the RSA and implementation of a proposed bankruptcy plan that would substantially restructure secured claims, issue new debt and equity, and provide an exit financing facility.
- Existing common interests are expected to be exchanged for approximately one share of reorganized-company common stock for every 25 existing shares, although the ratio remains subject to change.
- Existing equity holders are expected to receive two tranches of warrants and may participate in the Equity Rights Offering, subject to the Plan and applicable conditions.
Guidance, Outlook, Risks, and Unusual Items
- The company expects the Plan’s effective date in late December 2023 or early January 2024. The RSA sets an outside date of February 19, 2024, extendable to March 19, 2024 with required consents.
- The Bankruptcy Court was expected to enter a confirmation order by January 19, 2024, and Plan solicitation was to commence within seven calendar days after approval of the Disclosure Statement.
- The Rights Offering expires at 5:00 p.m. New York time on December 11, 2023. Each existing common interest held on November 16, 2023 was to receive one subscription right, initially allowing purchase of 0.01734 reorganized-company shares at an anticipated $8.21710 per share.
- The subscription price and share allocation may change based on miner-equipment-lender elections and disputed-claim estimates. Rights are non-transferable, and fractional shares will be rounded down.
- The restructuring remains subject to Bankruptcy Court approval, satisfaction of financing and other conditions, achievement of milestones, and potential termination rights. There is no assurance that the company will emerge from Chapter 11 or complete the restructuring on the stated terms.
- Major risks include liquidity pressure, increased restructuring costs, debt acceleration, adverse Bankruptcy Court rulings, third-party objections, failure to obtain or maintain debtor-in-possession or exit financing, failure to raise the required offering proceeds, and volatility associated with OTC trading.
- The filing contains forward-looking statements and does not provide operating or earnings guidance.
Most Important Facts for Investors to Verify
- Whether the Bankruptcy Court approved the Disclosure Statement and Plan and whether the company achieved the specified confirmation and effective-date milestones.
- Whether the RSA, Backstop Commitment Letter, or Exit Facility commitments were terminated, amended, or extended.
- The final treatment and allowed amounts of convertible-note, miner-equipment-lender, general unsecured, and equity claims.
- The final proceeds, subscription price, dilution, backstop premium, and share allocation under the Equity Rights Offering.
- The final exchange ratio and value of reorganized-company common stock and warrants issued to existing equity holders.
- The company’s post-emergence cash, debt, liquidity, operating performance, and ability to generate sustainable cash flow; these values are not provided in this filing.